Clinical Observation of Addition and Subtraction Therapy of Danggui Shaoyaosan Combined with Huaihuasan to Ulcerative Colitis with Syndrome of Dampness-heat in Large Intestine During Active Stage

Fang LIU; Na LEI; Xue-gui TANG

doi:10.13422/j.cnki.syfjx.20191832

您当前的位置：

首页 >

文章列表页 >

Clinical Observation of Addition and Subtraction Therapy of Danggui Shaoyaosan Combined with Huaihuasan to Ulcerative Colitis with Syndrome of Dampness-heat in Large Intestine During Active Stage

Clinic | 更新时间：2021-02-09

- Clinical Observation of Addition and Subtraction Therapy of Danggui Shaoyaosan Combined with Huaihuasan to Ulcerative Colitis with Syndrome of Dampness-heat in Large Intestine During Active Stage
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 25, Issue 20, Pages: 82-87(2019)
- 作者机构：
  
  1.川北医学院　附属医院，四川　南充　 637001；
  2.成都中医药大学，成都　 610015
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20191832
  CLC： R289; R5; R57; R574
- Received：16 April 2019，
  
  Published Online：28 May 2019，
  
  Published：20 October 2019
- 稿件说明：
移动端阅览
Fang LIU, Na LEI, Xue-gui TANG. Clinical Observation of Addition and Subtraction Therapy of Danggui Shaoyaosan Combined with Huaihuasan to Ulcerative Colitis with Syndrome of Dampness-heat in Large Intestine During Active Stage[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(20): 82-87.
DOI：

Fang LIU, Na LEI, Xue-gui TANG. Clinical Observation of Addition and Subtraction Therapy of Danggui Shaoyaosan Combined with Huaihuasan to Ulcerative Colitis with Syndrome of Dampness-heat in Large Intestine During Active Stage[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(20): 82-87. DOI： 10.13422/j.cnki.syfjx.20191832.

摘要

目的：

观察当归芍药散合槐花散加减治疗溃疡性结肠炎(UC)活动期大肠湿热证及对脑肠肽神经递质和炎细胞因子的影响。

方法：

共纳入130例随机按数字表法分成对照组和观察组各65例。对照组口服美沙拉嗪肠溶片1.0 g/次，3次/d；重度患者给予醋酸泼尼松片，0.75 mg·kg

－1

·d

－1

，分次口服。观察组在对照组治疗的基础上给予当归芍药散合槐花散加减内服，1剂/d。两组疗程均为连续治疗4周。进行治疗前后症状评分，Mayo评分、结肠黏膜评分和炎症性肠病问卷(IBDQ)评分；对于进入缓解期的患者进行6个月的随访，记录复发情况；检测治疗前后血管活性肠肽(VIP)，P物质(SP)，生长抑素(SS)，白细胞介素-1(IL-1)，IL-6，IL-4和IL-10。

结果：

经4周的治疗，观察组临床缓解率为93.22%，优于对照组的80.7%(

＝4.035，

0.05)；观察组患者各症状评分均低于对照组(

0.01)；观察组患者Mayo评分和结肠黏膜评分均低于对照组(

0.01)；观察组患者IBDQ量表各个维度评分和IBDQ总分均高于对照组(

0.01)；对临床缓解患者进行6个月随访，观察组复发率为18.18%，低于对照组的36.96%(

＝4.509，

0.05)，且复发时间长于对照组(

0.01)；观察组患者血清IL-1，IL-6水平均低于对照组(

0.01)，IL-4，IL-10水平均高于对照组(

0.01)；观察组患者血浆VIP和SS均高于对照组(

0.01)，SP水平低于对照组(

0.01)。

结论：

在西医常规治疗的基础上，当归芍药散合槐花散加减治疗UC(大肠湿热证)活动期患者，近期可控制疾病活动，促进结肠黏膜修复，远期可推迟复发，降低复发率，并可调节脑肠肽神经递质和促炎/抑炎细胞因子水平。

Abstract

Objective:

To observe the effects of addition and subtraction therapy of Danggui Shaoyaosan combined with Huaihuasan on ulcerative colitis (UC) with syndrome of dampness-heat in large intestine during active stage

and the effects on brain-gut petide neurotransmitter and inflammatory cytokines.

Method:

A total of 130 cases were included and randomly divided into control group and observation group

65 cases in each group. In the control group

the patients received oral administration of mesalazine enteric-coated tablets

1.0 g/time and 3 times/days. Severe patients received prednisone acetate tablets (0.75 mg·kg

-1

·d

-1

) in several times by oral administration. Based on the treatment in control group

patients in observation group also received addition and subtraction therapy of Danggui Shaoyaosan combined with Huaihuasan

1 dose/day. Both groups were treated for 4 weeks. Symptom scores

Mayo scores

colonic mucosa scores and Inflammatory Bowel Disease Questionnaire (IBDQ) scores were assessed before and after treatment. Patients in remission stage were followed up for 6 months to record the recurrence. Before and after treatment

vasoactive intestinal peptide (VIP)

substance P (SP)

somatostatin (SS)

interleukin-1 (IL-1)

IL-6

IL-4 and IL-10 were detected.

Result:

After 4 weeks of treatment

the clinical remission rate was 93.22%in the observation group

better than 80.7%in the control group (

=4.035

0.05). The scores of various symptoms in the observation group were lower than those in the control group (

0.01). The Mayo scores and colonic mucosal scores in the observation group were lower than those in the control group (

0.01). The IBDQ scores in all dimensions and the total IBDQ scores in the observation group were higher than those in the control group (

0.01). In 6 months of follow up for the patients in clinical remission stage

the recurrence rate in the observation group was 18.18%

lower than 36.96%in the control group (

=4.509

0.05)

and the recurrence time was longer than that in the control group (

0.01). The levels of serum IL-1 and IL-6 in the observation group were lower than those in the control group (

0.01)

and the levels of IL-4 and IL-10 were higher than those in the control group (

0.01). Plasma VIP and SS levels in the observation group were higher than those in the control group (

0.01)

while SP levels were lower than those in the control group (

0.01).

Conclusion:

On the basis of conventional western medicine treatment

addition and subtraction therapy of Danggui Shaoyaosan combined with Huaihuasan in the treatment of UC (dampness-heat in large intestine) during active stage can control the disease activity in a short term

promote restoration of the colonic mucosa. And delay the recurrence in a long term

reduce the recurrence rate

regulate ghrelin neurotransmitters and pro-and anti-inflammatory cytokines levels.

关键词

Keywords

references

李军祥，谭祥，毛堂友．溃疡性结肠炎中西医结合治疗策略 [J]．中国中西医结合杂志， 2017 ， 37 ( 4 )： 398 - 400 ．

中华中医药学会脾胃病分会．溃疡性结肠炎中医诊疗专家共识意见(2017) [J]．中国中西医结合杂志， 2017 ， 32 ( 8 )： 3585 - 3589 ．

刘笃佳，王媛媛，马旭．溃疡性结肠炎的流行病学研究进展 [J]．中国烧伤创疡杂志， 2017 ， 29 ( 3 )： 214 - 217 ．

张声生，赵鲁卿．溃疡性结肠炎的中医治疗策略和思考 [J]．中国中西医结合消化杂志， 2016 ， 24 ( 6 )： 411 - 413 ．

冯智，唐学贵，申旭龙，等．基于“血水同病”理论治疗溃疡性结肠炎的体会 [J]．成都中医药大学学报， 2015 ， 38 ( 3 )： 98-99，104 ．

冯智，王俊，李毅忠，等．溃疡性结肠炎“血水同病”模型的建立及评价 [J]．陕西中医药大学学报， 2018 ， 41 ( 2 )： 81 - 84 ．

李富震，白玉宾．当归芍药散治疗溃疡性结肠炎刍论 [J]．山东中医药大学学报， 2012 ， 36 ( 4 )： 285 - 286 ．

罗芬，原相军，占煜，等．仙方活命饮合槐花散加减治疗溃疡性结肠炎31例疗效观察 [J]．湖南中医杂志， 2014 ， 30 ( 1 )： 39 - 41 ．

中华医学会消化病学分会炎症性肠病协作组．对我国炎症性肠病诊断治疗规范的共识意见(2007年，济南) [J]．中华消化杂志， 2007 ， 27 ( 8 )： 545 - 550 ．

赵欣，恽海峰，向桂玲，等．白头翁汤加减联合双歧杆菌制剂对大鼠溃疡性结肠炎的影响 [J]．中国实验方剂学杂志， 2018 ， 24 ( 13 )： 110 - 116 ．

周璐，陆星华．炎症性肠病患者的健康相关生存质量 [J]．中华内科杂志， 2004 ， 43 ( 5 )： 392 - 394 ．

崔畅婉，孙峥嵘．溃疡性结肠炎发病机制研究进展 [J]．现代免疫学， 2019 ， 39 ( 1 )： 77 - 81 ．

刘思雨，刘建平，康欣，等．中医药抗溃疡性结肠炎复发的优势探究 [J]．河北中医药学报， 2018 ， 33 ( 3 )： 59-61，64 ．

刘果，孙慧怡，周波，等．益气活血解毒法抗溃疡性结肠炎复发的临床疗效评价 [J]．北京中医药大学学报， 2013 ， 36 ( 1 )： 51 - 55 ．

朱磊，沈洪，顾培青，等．沈洪教授治疗溃疡性结肠炎的经验探析 [J]．中华中医药杂志， 2015 ， 30 ( 7 )： 2381 - 2383 ．

李萌，宋冀，张文博，等．加味肠风饮保留灌肠对急性放射性直肠炎患者Th1/Th2的调节作用 [J]．中国实验方剂学杂志， 2019 ， 25 ( 1 )： 119 - 123 ．

谢伟昌，姜小艳，张竞超，等．基于“微生物-脑-肠轴”观察理肠汤对脾虚湿困型溃疡性结肠炎患者的作用 [J]．中国中西医结合消化杂志， 2018 ， 26 ( 12 )： 1013 - 1017 ．

李博林，张纨，王志坤，等．化浊解毒方治疗溃疡性结肠炎的临床疗效及对神经-内分泌-免疫网络的影响 [J]．中国中西医结合杂志， 2019 ， 39 ( 2 )： 184 - 188 ．

王益平，唐承薇．溃疡性结肠炎患者结肠黏膜生长抑素表达变化 [J]．现代实用医学， 2015 ， 27 ( 9 )： 1174 - 1175 ．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Regulatory Effect of Huaihuasan Combined with Taohuatang on Immune Inflammation During Active Period of Ulcerative Colitis with Cold-heat Syndrome

Anti-ulcerative Colitis Mechanism of Huaihuasan and Active Ingredients of Its Component Drugs： A Review

Nano Oral Colon Targeted Drug Delivery System in Treatment of Ulcerative Colitis： A Review

Comparison of Pharmacokinetics and Tissue Distribution of Free Anthraquinones and Gallic Acid in Mice with Ulcerative Colitis Before and After Processing of Rhei Radix et Rhizoma Carbonisata

Mechanisms of Zhuyuwan in Treating both Intrahepatic Cholestasis and Ulcerative Colitis Based on Homotherapy for Heteropathy

Related Author

Na LEI

Peng-fei KONG

Si-min CHEN

Xue-gui TANG

XU Xueli

GU Jiacheng

XI Zuowu

WANG Yanyan

Related Institution

Anorectal of Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

Anorectal of Affiliated Hospital of North Sichuan Medical College

Henan University of Chinese Medicine

Henan Province Hospital of Traditional Chinese Medicine/The Second Affiliated Hospital of Henan University of Chinese Medicine

Jiangxi University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰